Multi User License - $2,999
The Japanese pharmaceutical industry has experienced modest growth rates in recent years. It has been challenging for pharmaceutical companies to launch new, innovative drugs due to a complicated regulatory and pricing process, as well as ongoing price reductions.
The government decision to promote generic medications in an effort to lower healthcare costs in Japan is another factor contributing to the market’s stagnation.
Generics volume share has increased by more than a factor of two during the past ten years and is still growing.
In addition to the booming generic medication market, the planned change of the Japanese pharmaceutical industry will be fueled by a rise in the usage of biosimilars, which are predicted to have the quickest future growth rate due to the wide range of medicines now in development.
Japanese corporations are being forced to adjust to a shifting market climate as several medicine patents have started to expire.
With a proportion in the global market, the Japanese pharmaceutical industry is still among the largest. The Japanese market is changing, but it also presents a number of opportunities and room for expansion.
The Japan pharmaceuticals market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
When the SARS-CoV-2 virus caused the coronavirus disease (COVID-19) to spread, pharmaceutical companies all over the world tried to produce medicines to treat or cure the illness.
According to the extra budget plans after the outbreak, the Japanese government mostly sponsored overseas partnerships instead of domestically creating the vaccine.
Nevertheless, five domestically produced vaccinations are presently undergoing testing. The first COVID-19 vaccine, the mRNA vaccine, was licensed by the Japanese government.
Then, vaccinations started for medical personnel mostly for adults. The viral vector vaccine and mRNA vaccine from AstraZeneca were authorised.
Following clearance, the Moderna vaccine was administered in conjunction with Takeda Pharmaceutical Company Limited, the regional distributor.
Due to adverse effects experienced by older individuals that were reported internationally, AstraZeneca’s vaccine was only initially distributed to the elderly.
The government switched over to the recombinant protein-based vaccination Novavax in place of AstraZeneca’s, with Takeda serving as the regional producer and distributor.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.